Elite Pharmaceuticals Inc Revenue Growth Rates (ELTP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Elite Pharmaceuticals Inc   (ELTP)
 

ELTP's Revenue Growth by Quarter and Year

Elite Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELTP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 32.36
FY 32.36

ELTPs Annual Revenue
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2026 $ 148.87 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 83.09 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 56.36 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 33.59 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 31.80 millions




ELTP Revenue first quarter 2026 Y/Y Growth Comment
Elite Pharmaceuticals Inc reported decline in Revenue in the first quarter 2026 by -17.52% to $ 32.36 millions, from the same quarter in 2025.
The contraction in the first quarter 2026 Elite Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 42.12%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue growth. While Elite Pharmaceuticals Inc ' s Revenue fall of -17.52% ranks overall at the positon no. 779 in the first quarter 2026.


ELTP Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter March - 26.16 % 68.93 % 121.3 %
3rd Quarter December - 119.19 % -6.12 % 68.61 %
2nd Quarter September - 98.19 % 35.32 % 71.99 %
1st Quarter June -17.52 % 112.4 % 111.09 % 25 %
FY   - 76.92 % 47.43 % -

Financial Statements
Elite Pharmaceuticals Inc 's first quarter 2026 Revenue $ 32.36 millions ELTP's Income Statement
Elite Pharmaceuticals Inc 's first quarter 2025 Revenue $ 39.23 millions Quarterly ELTP's Income Statement


ELTP Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter March - 31.66 % 128.75 % 27.13 %
3rd Quarter December - -14.19 % -22.42 % 11.82 %
2nd Quarter September - -8.06 % -1.46 % 53.71 %
1st Quarter June -20.6 % 21.46 % -3.4 % 1.27 %
FY (Year on Year)   - 76.92 % 47.43 % -


Back to ELTP Growth rate Comparisons >> Back to ELTP Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #157
Overall #779

Revenue Y/Y Growth Statistics
High Average Low
242.28 % 42.12 % -47.5 %
(Mar 31 2016)   (Sep 30 2017)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #157
Overall #779
Revenue Y/Y Growth Statistics
High Average Low
242.28 % 42.12 % -47.5 %
(Mar 31 2016)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Elite Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
473.73 % 20.56 % -72.31 %
(Jun 30 2015)  


ELTP's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Elite Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -20.6% to $ 32.36 millions, from $ 40.75 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 184 other companies have achieved higher Revenue quarter on quarter growth. While Elite Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3584.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #185
Healthcare Sector #524
Overall #3584
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #185
Healthcare Sector #524
Overall #3584
Revenue Q/Q Growth Statistics
High Average Low
473.73 % 20.56 % -72.31 %
(Jun 30 2015)  


ELTP's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Elite Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -20.6% to $ 32.36 millions, from $ 40.75 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 184 other companies have achieved higher Revenue quarter on quarter growth. While Elite Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3584.


Elite Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 140.13 $ 147.00 $ 138.55 $ 121.71 $ 103.84
Y / Y Revenue Growth (TTM) 34.95 % 76.92 % 98.18 % 71.83 % 57.14 %
Year on Year Revenue Growth Overall Ranking # 359 # 396 # 94 # 132 # 92
Seqeuential Revenue Change (TTM) -4.67 % 6.1 % 13.83 % 17.21 % 24.98 %
Seq. Revenue Growth (TTM) Overall Ranking # 779 # 913 # 1508 # 1315 # 657


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Elite Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 140 millions, company would post below average annual Revenue growth of 24.98% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Elite Pharmaceuticals Inc 's Revenue growth from the 40.75% growth in Mar 31 2026.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 359, from total ranking in previous quarter at 396.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 89
Overall # 359

Revenue TTM Y/Y Growth Statistics
High Average Low
242.28 %
 42.12 %
-47.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 157
S&P 500 # 779
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Elite Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 140 millions, company would post below average annual Revenue growth of -47.5% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Elite Pharmaceuticals Inc 's Revenue growth from the 40.75% growth in Mar 31 2026.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 359, from total ranking in previous quarter at 396.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 89
Overall # 359

Revenue TTM Y/Y Growth Statistics
High Average Low
242.28 %
42.12 %
-47.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 157
S&P 500 # 779




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ELTP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Elite Pharmaceuticals Inc Revenue Growth Rates (ELTP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Elite Pharmaceuticals Inc Nv (CIK 1053369).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-037752
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Elite Pharmaceuticals Inc Nv’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.